Newsroom
Newsroom
October 4, 2011
Humacyte's groundbreaking new technology to create "off the shelf" human veins for use in life-saving vascular surgeries has been recognized by Popular Mechanics magazine as one of the "Breakthrough" innovations of 2011 that is "changing our world for the better." Humacyte founder, Laura Niklason and co-founders Shannon Dahl and Juliana Blum will accept the award during a ceremony at the Hearst Tower in New York City on Monday, October 10, 2011.
Read Full Press Release
September 13, 2011
The Humacyte bioengineered vein technology was recognized with the 2011 North American New Product Innovation Award in the Vascular Grafts market by Frost & Sullivan. Frost & Sullivan is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies.
Read Full Press Release
February 2, 2011
Humacyte, Inc. announces new research published in the current issue of the journal, Science Translational Medicine, demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately-available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis.
Read Full Press Release
Read publication in Science Translational Medicine
November 11, 2010
Work being done on bioengineering lungs at Humacyte's founder, Laura Niklason's Yale University research lab, was named to TIME Magazine's list of "The 50 Best Inventions of 2010".
November 1, 2010
Humacyte, Inc. announces today that the company has been awarded a grant of $244,479.25 under the Qualify Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010.
September 7, 2010
Humacyte, Inc., a pioneer in regenerative medicine, today announced the appointment of Carrie S. Cox as Chief Executive Officer and a member of the company's Board of Directors, effective Sept. 20, 2010. Cox, a 30-year veteran of the pharmaceutical industry, brings a wealth of experience to Humacyte at a time when the company is moving into its next exciting development phase.
Read Full Article
February 1, 2010
Humacyte, Inc. announces today that they have been awarded an SBIR Phase I grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of novel manufacturing process for their tissue engineered vascular grafts.
r